论文部分内容阅读
Based on the principles of the bioisosterism, combination of the active substructures of selective estrogen receptor modulators which are currently therapeutic agents available for the prevention and treatment of various es-trogen dependent diseases, and structural optimization, a novel series of 2-aroyl-3-aryl-6,7-dihydro-5H-furo[3,2-g]-chromen derivatives was designed as potent selective estrogen receptor modulators via molecular docking. The target compounds have been synthesized, and characterized by IR, proton NMR, ESI-MS, elemental analysis and evaluated for their antitumor activity against human osteosarcoma U2OS-EGFP-4F12G cell line. Some target compounds showed good inhibition effects on U2OS-EGFP-4F12G cell line and the preliminary structure-activity relationships were discussed.
Based on the principles of the bioisosterism, combination of the active substructures of selective estrogen receptor modulators which are currently therapeutic agents available for the prevention and treatment of various es-trogen dependent diseases, and structural optimization, a novel series of 2-aroyl-3 -aryl-6,7-dihydro-5H-furo [3,2-g] -chromen derivatives were designed as potent selective estrogen receptor modulators via molecular docking. The target compounds have been synthesized, and characterized by IR, proton NMR, ESI -MS, elemental analysis and evaluated for their antitumor activity against human osteosarcoma U2OS-EGFP-4F12G cell line. Some target compounds showed good inhibition effects on U2OS-EGFP-4F12G cell line and the preliminary structure-activity relationships were discussed.